


## PHARMACEUTICAL 2021









## PHARMACEUTICAL 2021



## CASSAVA SCIENCES INC Rank 27 of 409



The relative strengths and weaknesses of CASSAVA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CASSAVA SCIENCES INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 172% points. The greatest weakness of CASSAVA SCIENCES INC is the variable Revenues, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 157%, being 512% points above the market average of -355%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 93,994            |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 1,865             |
| Liabilities, Non-Current                    | 235               |
| Other Assets                                | 295               |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 2,707             |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 0                 |
| Property and Equipment                      | 11                |
| Research and Development                    | 0                 |
| Revenues                                    | 112               |
| Selling, General and Administrative Expense | 3,739             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 94,300            |
| Liabilities              | 2,100             |
| Expenses                 | 6,446             |
| Stockholders Equity      | 92,200            |
| Net Income               | -6,334            |
| Comprehensive Net Income | -6,334            |
| Economic Capital Ratio   | 157%              |